Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records β€” linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review claims



    Explore by Goal












     Quick Explanation


    Yang Li β€” scientific strength review (evidence-anchored, skeptical)
    Your input does not provide an unambiguous mapping from β€œYang Li” to each DOI excerpt. So below I evaluate only what is directly supported by the provided DOI-based research excerpts, and I explicitly flag where attribution/generalization is uncertain.



     Long Explanation


    Yang Li β€” Author Review (rigorous + attribution-skeptical)
    Core limitation: The prompt supplies (i) bibliometrics for an individual named β€œYang Li”, and (ii) many full DOI-based research excerpts. However, the input does not explicitly prove that the DOIs’ corresponding authors are the same β€œYang Li”. Therefore, I treat the DOIs as evidence snippets contained in your provided research payload, not as guaranteed authorship by the reviewed person.

    1) What is actually supported by the provided payload?

    • Attribution uncertainty: Without explicit β€œYang Li” ↔ DOI authorship links, any statement about β€œYang Li’s scientific work” across these DOIs is inherently uncertain. That reduces confidence in author-level claims.
    • Evidence strength can still be judged at the paper/excerpt level (study design, controls, model systems, mechanistic logic, reproducibility signals) using the DOI excerpts you supplied.
    • Biological relevance across fields is broad (circRNA cancer regulation, ESC differentiation circuitry, device physics, CRISPR nuclease specificity, protein/nanocage engineering, etc.). Broad topic spread can indicate either interdisciplinary strength or possible bibliometric name-collisionsβ€”this needs DOI↔author validation.

    2) Evidence visualizations from the provided DOI excerpts (paper-level)

    The following figures are generated from numbers explicitly included in your provided research excerpts (not re-inferred).
    Source (PCE/Voc/FF values): the excerpt explicitly states Ta2O5 yields β€œPCE up to 10.95% (Voc β‰ˆ 0.695 V, FF β‰ˆ 67.87%)” and β€œcertified PCE 10.65% (Voc β‰ˆ 0.692 V, Jsc β‰ˆ 22.42 mA cmβˆ’2, FF β‰ˆ 68.70%).”
    Source (TAS/TPV lifetimes): excerpt states β€œTAS carrier lifetimes (252 ΞΌs Ta2O5 vs 328 ΞΌs control)” and β€œTPV carrier recombination lifetimes (3238 ΞΌs Ta2O5 vs 953 ΞΌs control).”
    Source: the payload’s extracted circRNA dataset includes circMAN1A2(2,3,4,5) copy numbers β€œHT29: 92, DLD-1: 23” and CENPB mRNA copy numbers β€œHT29: 19, DLD-1: 13.”
    Note: β€œcopy numbers” appear as excerpted values from the prompt payload; without the full methods section, I cannot verify the unit basis or measurement calibration.

    3) Critical appraisal: what the excerpted studies suggest (and what they cannot prove)

    3.1 Mechanistic circRNA cancer regulation (circMAN1A2(2,3,4,5) β†’ CENPB mRNA via IGF2BP2)
    • Strengths in the payload excerpt: multi-layer evidence for a direct circRNA–mRNA interaction is described as including β€œAMT-crosslinking RNA pull-down,” β€œin-cell and in vitro RNA pull-downs,” β€œEMSA,” β€œRIP showing IGF2BP2–CENPB mRNA interaction,” plus functional knockdown and LNA blocking assays.
    • Key uncertainty / falsifiability constraint: the excerpt itself flags species/context specificity: β€œeffect is human-specific (not conserved in mice) in the tested context,” which limits generalization.
    • Potential blind spots: LNA blocking can have off-target hybridization effects; ribo-RNA-seq detection and normalization can bias circRNA quantification. Those risks are stated in the payload limitations.
    3.2 Transcriptional circuitry in pluripotency β†’ PrE (Nanog–TBX3–GATA6 via enhancer/promoter remodeling)
    • Strengths: the payload excerpt indicates integration of RNA-seq/ChIP-seq/Co-IP and CRISPR/activator-based enhancer manipulation (dCas9-VPR), plus reporter assays and rescue logic.
    • Limitations that matter mechanistically: the payload highlights primarily in vitro conclusions, potential CRISPR off-targets, and reliance on overexpression/knockdown systems rather than endogenous perturbation dynamics.
    3.3 CRISPR specificity via a hypercompact CRISPR-Cas12j nuclease (Cas12j-8 allele-specific editing)
    • Strengths: the payload excerpt includes both reporter-based activity screening and genome-wide off-target mapping (β€œGUIDE-seq”), plus in silico PAM landscape and deep sequencing of edits across multiple loci.
    • Translational uncertainty: payload explicitly notes in vivo editing efficiency, long-term safety, and immunogenicity are not comprehensively addressed in the provided excerpt.
    3.4 Protein/nanocage engineering for mRNA delivery (AI-guided human endogenous nanocages; TRIM-domain engineering)
    • Strengths: the payload describes a large proteome-scale screening with dual models and experimentally validating β€œ12 of 15 formed nanocages delivered functional mRNA,” plus innate immune profiling in macrophage-like cells.
    • Limits: payload notes largely in vitro validation; missing in vivo biodistribution/safety; potential training-set biases; and limited candidate count even after large screening.

    4) Overall judgment: β€œYang Li” scientific strength (with attribution caveats)

    • If the provided DOI excerpts are indeed attributable to the reviewed β€œYang Li”, the payload shows competence across: (a) mechanistic RNA biology with multi-assay validation, (b) enhancer circuitry with chromatin profiling and genetic perturbations, (c) genome engineering specificity using deep sequencing + GUIDE-seq, and (d) protein engineering using AI + wet-lab validation.
    • If not, then the excerpt set only demonstrates that your payload contains strong-looking papers, not that the reviewed person authored them. That makes author-level rigor/note comparisons unreliable.
    • Therefore: I assign moderate confidence in author-level claims and emphasize the missing mapping as the dominant epistemic uncertainty.
    What would disprove/upgrade confidence? A clean β€œYang Li” ↔ DOI author list mapping (e.g., via ORCID, PubMed/semantic scholar pages, or the OpenAlex record for the same identity) and the actual full-text results (not just excerpts) including raw/processed files and replication details.

    5) Suggested next BGPT actions (to remove attribution ambiguity)

    These actions directly address the largest uncertainty in your current dataset.


    Feedback:    

    Updated: March 23, 2026

     BGPT Author Review


    Scientific Quality

    40%

    The evidence payload contains multiple high-rigor mechanistic excerpts with modern methodologies (e.g., crosslinking pull-down/EMSA for RNA-RNA interactions; CRISPR+ChIP-seq circuitry; GUIDE-seq off-target profiling; AI+wet-lab validation). However, the prompt does not unambiguously map those DOIs to the specific reviewed individual β€œYang Li”, creating a major attribution risk/name-collision possibility. Because author-level scientific quality is judged by biological merit, and that merit cannot be cleanly linked to the person with the provided info, the score is capped. If mapping is verified, the score could rise substantially; without it, rigor assessment remains weakly grounded.


    Communication Quality

    60%

    Communication quality cannot be assessed from the provided text because no full β€œYang Li” author narrative, writing samples, figures, or abstracts are givenβ€”only structured excerpts and bibliometrics-like fields. The prompt’s provided one-sentence summaries are clear, but that reflects the payload formatting rather than author prose. Hence a mid score is assigned for only indirect clarity signals.


    Author Novelty

    50%

    Novelty is indeterminate at the author level because the prompt does not tie the described novelty claims to the specific individual. Some excerpts suggest cutting-edge approaches (hypercompact CRISPR, AI-guided protein nanocages, circRNA direct RNA-RNA mechanisms), but novelty attribution to β€œYang Li” is uncertain due to missing author-to-DOI mapping.


    Scientific Rigor

    40%

    The excerpted studies appear methodologically ambitious and include multiple orthogonal assays and explicit limitations (improving rigor at the paper level). Yet author-level rigor cannot be confirmed without mapping the studies to the reviewed person. Additionally, several payload sections rely on excerpted numeric values whose measurement basis is not fully verifiable from the prompt alone, further weakening rigor confidence.

     Top Data Sources ExportMCP


     Analysis Wizard



    I is analyzing the provided circRNA excerpt to automatically extract all numeric values (copy numbers, expression/coherence flags) and generate QC-style summary plots, then outputs a clean table for auditability.



     Hypothesis Graveyard


    A β€œhuman-universal circRNA” claim will not be falsified by the mere existence of some species differences; instead, it would be falsified when orthogonal quantification pipelines disagree on universality or when independent cohorts fail to reproduce the same KD phenotype.


    High specificity nucleases will not eliminate off-target risk entirely; if GUIDE-seq-like profiling underestimates rare long-tail events, the idea that nuclease PAM rules alone guarantee safety would be weakened by deeper unbiased profiling.

     Science Art


    Author Review: Yang Li Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending